Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 171

1.

Predictors of rapid cognitive decline in Alzheimer's disease: results from the Australian imaging, biomarkers and lifestyle (AIBL) study of ageing.

Sona A, Zhang P, Ames D, Bush AI, Lautenschlager NT, Martins RN, Masters CL, Rowe CC, Szoeke C, Taddei K, Ellis KA; AIBL Research Group.

Int Psychogeriatr. 2012 Feb;24(2):197-204. doi: 10.1017/S1041610211001335. Epub 2011 Jul 13.

PMID:
21749739
2.

Diagnosis of Alzheimer's disease patients with rapid cognitive decline in clinical practice: interest of the Deco questionnaire.

Carcaillon L, Berrut G, Sellal F, Dartigues JF, Gillette S, Pere JJ, Bourdeix I.

J Nutr Health Aging. 2011 May;15(5):361-6.

PMID:
21528162
3.

Predictive value of rapid decline in mini mental state examination in clinical practice for prognosis in Alzheimer's disease.

Soto ME, Andrieu S, Cantet C, Reynish E, Ousset PJ, Arbus C, Gillette-Guyonnet S, Nourhashémi F, Vellas B; REAL.FR group.

Dement Geriatr Cogn Disord. 2008;26(2):109-16. doi: 10.1159/000144073. Epub 2008 Jul 11.

PMID:
18617740
4.

The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease.

Ellis KA, Bush AI, Darby D, De Fazio D, Foster J, Hudson P, Lautenschlager NT, Lenzo N, Martins RN, Maruff P, Masters C, Milner A, Pike K, Rowe C, Savage G, Szoeke C, Taddei K, Villemagne V, Woodward M, Ames D; AIBL Research Group.

Int Psychogeriatr. 2009 Aug;21(4):672-87. doi: 10.1017/S1041610209009405. Epub 2009 May 27.

PMID:
19470201
5.

The cognitive benefits of galantamine are sustained for at least 36 months: a long-term extension trial.

Raskind MA, Peskind ER, Truyen L, Kershaw P, Damaraju CV.

Arch Neurol. 2004 Feb;61(2):252-6.

PMID:
14967774
6.

Cognitive decline is faster in Lewy body variant than in Alzheimer's disease.

Olichney JM, Galasko D, Salmon DP, Hofstetter CR, Hansen LA, Katzman R, Thal LJ.

Neurology. 1998 Aug;51(2):351-7.

PMID:
9710002
7.

Functional response to cholinesterase inhibitor therapy in a naturalistic Alzheimer's disease cohort.

Wattmo C, Wallin AK, Minthon L.

BMC Neurol. 2012 Nov 5;12:134. doi: 10.1186/1471-2377-12-134.

8.

Predicting disease progression in Alzheimer's disease: the role of neuropsychiatric syndromes on functional and cognitive decline.

Palmer K, Lupo F, Perri R, Salamone G, Fadda L, Caltagirone C, Musicco M, Cravello L.

J Alzheimers Dis. 2011;24(1):35-45. doi: 10.3233/JAD-2010-101836.

PMID:
21157019
9.

Effectiveness and safety of cholinesterase inhibitors in elderly subjects with Alzheimer's disease: a "real world" study.

Mossello E, Tonon E, Caleri V, Tilli S, Cantini C, Cavallini MC, Bencini F, Mecacci R, Marini M, Bardelli F, Sarcone E, Razzi E, Biagini CA, Masotti G.

Arch Gerontol Geriatr Suppl. 2004;(9):297-307.

PMID:
15207427
10.

A 2-year follow-up of 233 very mild (CDR 0.5) Alzheimer's disease patients (REAL.FR cohort).

Nourhashémi F, Ousset PJ, Gillette-Guyonnet S, Cantet C, Andrieu S, Vellas B; REAL.FR cohort.

Int J Geriatr Psychiatry. 2008 May;23(5):460-5.

PMID:
17894422
11.

[Validation of the Short Cognitive Battery (B2C). Value in screening for Alzheimer's disease and depressive disorders in psychiatric practice].

Robert PH, Schuck S, Dubois B, Lépine JP, Gallarda T, Olié JP, Goni S, Troy S.

Encephale. 2003 May-Jun;29(3 Pt 1):266-72. French.

PMID:
12876552
12.

Fast cognitive decline at the time of dementia diagnosis: a major prognostic factor for survival in the community.

Carcaillon L, Pérès K, Péré JJ, Helmer C, Orgogozo JM, Dartigues JF.

Dement Geriatr Cogn Disord. 2007;23(6):439-45. Epub 2007 Apr 26.

13.

Predictive factors for rapid loss on the mini-mental state examination in Alzheimer's disease.

Dumont C, Voisin T, Nourhashemi F, Andrieu S, Koning M, Vellas B.

J Nutr Health Aging. 2005;9(3):163-7.

PMID:
15864396
14.

Diabetes is associated with a slower rate of cognitive decline in Alzheimer disease.

Sanz C, Andrieu S, Sinclair A, Hanaire H, Vellas B; REAL.FR Study Group.

Neurology. 2009 Oct 27;73(17):1359-66. doi: 10.1212/WNL.0b013e3181bd80e9.

PMID:
19858457
15.

Apolipoprotein E genotype and rate of decline in probable Alzheimer's disease.

Dal Forno G, Rasmusson DX, Brandt J, Carson KA, Brookmeyer R, Troncoso J, Kawas CH.

Arch Neurol. 1996 Apr;53(4):345-50.

PMID:
8929157
16.

A longitudinal study of Alzheimer's disease: rates of cognitive and functional decline.

Suh GH, Ju YS, Yeon BK, Shah A.

Int J Geriatr Psychiatry. 2004 Sep;19(9):817-24.

PMID:
15352138
17.

Predictive value of 6-month decline in ADAS-cog for survival without severe Alzheimer's disease.

Helmer C, Andrieu S, Pérès K, Orgogozo JM, Vellas B, Dartigues JF; REAL.fr Group.

Dement Geriatr Cogn Disord. 2007;23(3):168-74. Epub 2007 Jan 11.

PMID:
17215578
18.

Prognosis of Alzheimer's disease today: a two-year prospective study in 686 patients from the REAL-FR Study.

Cortes F, Nourhashémi F, Guérin O, Cantet C, Gillette-Guyonnet S, Andrieu S, Ousset PJ, Vellas B; REAL-FR Group.

Alzheimers Dement. 2008 Jan;4(1):22-9. doi: 10.1016/j.jalz.2007.10.018.

PMID:
18631947
19.

Rapid cognitive decline in Alzheimer's disease. Consensus paper.

Soto ME, Andrieu S, Arbus C, Ceccaldi M, Couratier P, Dantoine T, Dartigues JF, Gillette-Guyonnet S, Nourhashemi F, Ousset PJ, Poncet M, Portet F, Touchon J, Vellas B.

J Nutr Health Aging. 2008 Dec;12(10):703-13.

PMID:
19043645
20.

Rates of diagnostic transition and cognitive change at 18-month follow-up among 1,112 participants in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL).

Ellis KA, Szoeke C, Bush AI, Darby D, Graham PL, Lautenschlager NT, Macaulay SL, Martins RN, Maruff P, Masters CL, McBride SJ, Pike KE, Rainey-Smith SR, Rembach A, Robertson J, Rowe CC, Savage G, Villemagne VL, Woodward M, Wilson W, Zhang P, Ames D; AIBL Research Group.

Int Psychogeriatr. 2014 Apr;26(4):543-54. doi: 10.1017/S1041610213001956. Epub 2013 Nov 20.

PMID:
24252258
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk